Imlifidase

Phase 3

Hansa Biopharma AB (HNSA.ST)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Feb '27

HNSA.STPhase 2$322M

Imlifidase Phase 2 Est. Readout

Imlifidase• Kidney Transplantation in Highly Sensitized Patients10

Feb 2027~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Kidney Transplantation in Highly Sensitized Patients

View Full Landscape

Drug Information

Target Indication

Kidney Transplantation in Highly Sensitized Patients

Clinical Trial

NCT04935177

Last updated: 6/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/25/2020

Idefirix

Idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. The use of Idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

OrphanConditionalPRIME

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

HNSA.ST

Hansa Biopharma AB

Pharmaceutical Preparations•Europe•Nasdaq Stockholm

Related Pipeline

Imlifidase administered in the 20-HMedIdeS-19 (PAES) studyPhase 3

Long Term Efficacy and Safety

IdeSPhase 2